These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20608988)

  • 21. Testosterone and blood pressure regulation.
    Kienitz T; Quinkler M
    Kidney Blood Press Res; 2008; 31(2):71-9. PubMed ID: 18319594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The relationship between genetic polymorphisms and disease, illustrated by the renin-angiotensin-aldosterone system and cardiovascular disease].
    Spiering W; Kroon AA; Vreugdenhil HA; Geraedts JP; Daemen MJ; de Leeuw PW
    Ned Tijdschr Geneeskd; 1998 Jun; 142(25):1445-50. PubMed ID: 9752056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The renin-angiotensin-aldosterone system and fibrinolysis.
    Felmeden DC; Lip GY
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney.
    McGuire BB; Watson RW; Pérez-Barriocanal F; Fitzpatrick JM; Docherty NG
    Kidney Blood Press Res; 2007; 30(2):67-80. PubMed ID: 17268203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
    Usalan C; Buyukhatipoglu H
    Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the renin-angiotensin-aldosterone system for control of arterial blood pressure following moderate deficit in total body sodium: balance studies in freely moving dogs.
    Seeliger E; Lunenburg T; Ladwig M; Reinhardt HW
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):e43-51. PubMed ID: 19930429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K; Cooper ME
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences?
    Klotz S; Burkhoff D; Garrelds IM; Boomsma F; Danser AH
    Eur Heart J; 2009 Apr; 30(7):805-12. PubMed ID: 19223317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [What is the purpose of dual or triple inhibition of the renin-angiotensin-aldosterone system?].
    Legrand D; Krzesinski JM; Scheen AJ
    Rev Med Suisse; 2008 Aug; 4(168):1792-7. PubMed ID: 18814762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in hypertension: contribution of the renin-angiotensin system.
    Maric-Bilkan C; Manigrasso MB
    Gend Med; 2012 Aug; 9(4):287-91. PubMed ID: 22795464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
    Cooper ME
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activity of renin-angiotensin-aldosterone system (RAAS) and vasopressin level in patients with primary pulmonary hypertension].
    Martyniuk TV; Chazova IE; Masenko VP; Volkov VN; Belenkov IuN
    Ter Arkh; 1998; 70(4):33-6. PubMed ID: 9612899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Renin-angiotensin-aldosterone system (RAAS) and its pharmacologic modulation].
    Giestas A; Palma I; Ramos MH
    Acta Med Port; 2010; 23(4):677-88. PubMed ID: 20687997
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin-angiotensin-aldosterone system and progression of renal disease.
    Rüster C; Wolf G
    J Am Soc Nephrol; 2006 Nov; 17(11):2985-91. PubMed ID: 17035613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered regulation of renin-angiotensin, endothelin and natriuretic peptide systems in rat kidney with chronic unilateral ureteral obstruction.
    Bae EH; Kim IJ; Park JW; Ma SK; Choi KC; Lee JU; Kim SW
    Urol Int; 2007; 79(2):170-6. PubMed ID: 17851289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.